Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07201051 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis
A Phase 2 study, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 446
- Enrollment target
NCT07201051 is a Phase 2 study that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 446 participants.
The verdict
NCT07201051, a Phase 2 study, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 446 participants
- Enrollment target
Study Summary
This study is designed to find out how effective and safe a new drug, GSK3862995B, is for adult participants with bronchiectasis, a chronic lung disease. The study will also test how the body processes the drug and to check for any immune reactions. Participants will be divided into groups randomly to receive either one of two different doses of the study drug or a placebo. The main goal of the study is to see how well the drug works compared to the placebo in helping those with bronchiectasis.
Interventions
- DRUG Placebo
- DRUG GSK3862995B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 446 participants |
| Start Date | 2025-10-30 |
| Est. Completion | 2027-12-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07201051
The ClinicalTrials.gov registry entry for NCT07201051 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 446 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07201051 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07201051 about?
NCT07201051 is a clinical study titled "A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis". This study is designed to find out how effective and safe a new drug, GSK3862995B, is for adult participants with bronchiectasis, a chronic lung disease. The study will also test how the body processes the drug and to check for any immune reactions. Participants will be divided into groups randomly ...
What is the current status of trial NCT07201051?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 446 participants. The study started on 2025-10-30. Estimated completion is 2027-12-10.
What interventions are being tested in trial NCT07201051?
The interventions under investigation include: Placebo (DRUG), GSK3862995B (DRUG).
Who is sponsoring clinical trial NCT07201051?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.